Penka Slavtcheva Slavova-Petrova

Title: Penka Slavtcheva Slavova-Petrova: Innovator in Cancer Treatment

Introduction

Penka Slavtcheva Slavova-Petrova is a prominent inventor based in Toronto, Canada. She has made significant contributions to the field of cancer treatment through her innovative research and patented technologies. With a total of 2 patents, her work focuses on targeting CD47+ disease cells, which are often associated with various forms of cancer.

Latest Patents

Her latest patents include groundbreaking methods for treating CD47+ disease cells using SIRPα-Fc fusions. These patents describe a human SIRPα fusion protein that effectively blocks signaling via the SIRPα/CD47 axis. The fusion protein is designed to have negligible CD47 agonism and minimal binding to red blood cells. It comprises an IgV domain from variant 2 of human SIRPα, which binds human CD47 with an affinity that is at least five times greater than that of the entire extracellular region of human SIRPα. This innovative approach results in a fusion protein that is at least five times more potent than counterparts lacking effector function.

Career Highlights

Penka is currently associated with Trillium Therapeutics Inc., where she continues to advance her research in cancer therapies. Her work is pivotal in developing treatments that could potentially improve outcomes for patients with CD47+ cancers.

Collaborations

Throughout her career, Penka has collaborated with notable colleagues, including Robert Adam Uger and Xinli Pang. These collaborations have further enriched her research and contributed to the success of her innovative projects.

Conclusion

Penka Slavtcheva Slavova-Petrova is a trailblazer in the field of cancer treatment, with her patents paving the way for new therapeutic strategies. Her dedication to innovation and collaboration highlights the importance of research in combating cancer.